Pila Pharma (PILA) Q4 2024 earnings summary

Executive summary

• Focused on developing the TRPV1 antagonist XEN-D0501 for obesity, diabetes, and related disorders, with promising preclinical and safety data from prior trials involving 300 humans and additional potential in cardiovascular disease and pain management.

• 2024 saw increased R&D activity, management changes, and a successful SEK 10 million share issue, with progress in clinical and preclinical programs.

• Lead candidate XEN-D0501 demonstrated preclinical proof-of-concept in reducing abdominal aorta aneurysm growth in mice.

• Company operates a virtual organization, leveraging consultants and CROs for R&D.

• No negative surprises in the financials; cash position remains stable, and cash burn aligned with forecasts.

Financial highlights

• Ended 2024 with SEK 6.4 million in cash across Swedish and Danish entities; cash and cash equivalents at year-end were TSEK 4,893.

• Operating income for 2024 was TSEK 790, down from TSEK 1,463 year-over-year.

• Operating result (EBIT) for 2024 was TSEK -8,109, compared to TSEK -6,393 in 2023.

• Net result for 2024 was TSEK -11,241, versus TSEK -9,930 in 2023.

• Cash burn increased year-over-year due to ramped-up activities for the obesity trial.

Outlook and guidance

• Phase II-A obesity/diabetes trial planned, targeting 30-40 patients with dose escalation and mechanistic measurements; regulatory feedback pending.

• Sufficient financing secured for the next twelve months to fund existing commitments.

• Ongoing discussions with UK authorities have delayed the trial start, but preparations continue.

• Actively seeking partnerships to advance the molecule, aiming for a deal post-phase II rather than self-funding phase III.